Well Referenced

Tag: mistletoe therapy

Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients

This 2020 observational study (Integrative Cancer Therapies, PMID: 32478590) evaluated the impact of add-on Viscum album L. (mistletoe) therapy on cancer-related fatigue, internal coherence, and quality of life in 319 nonmetastasized breast cancer patients over 24 months. While chemotherapy, immunotherapy, and endocrine therapies were associated with worsened fatigue (by 17,

Read More »
June 26, 2025 No Comments

Patient’ and social aspects related to complementary mistletoe therapy in patients with breast cancer: A systematic review commissioned by the German agency for Health Technology Assessment

This 2023 systematic review (European Journal of Oncology Nursing, PMID: 37321128) analyzed patient and social perspectives on the use of mistletoe therapy in breast cancer care. The review found that mistletoe therapy is frequently used among breast cancer patients, despite limited scientific understanding by both patients and healthcare providers. The

Read More »
June 26, 2025 No Comments

Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone – efficacy and safety, costs and cost-effectiveness, patients and social aspects, and ethical assessment

This randomized controlled trial examined the effects of mistletoe extracts as a complementary therapy for breast cancer patients undergoing chemotherapy. The study found that mistletoe therapy significantly improved quality of life by alleviating chemotherapy-related fatigue, enhancing physical and emotional well-being. However, it did not impact cancer progression or survival rates.

Read More »
June 26, 2025 No Comments

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments